Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adimab, a US based integrated antibody discovery and optimization platform provider, has signed two different agreements with Biogen Idec and Novo Nordisk.
Subscribe to our email newsletter
Under collaboration with the Danish Novo Nordisk, Adimab will use its proprietary discovery platform for identifying fully human antibodies against two targets selected by Novo Nordisk.
The tie up with Novo allows Adimab to get upfront payments and preclinical milestones from Novo.
Novo is also responsible to pay clinical development milestones and royalties on product sales to Adimab.
Additionally, under pact with Biogen Idec, Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Biogen Idec.
Under the contract, Biogen is responsible to pay upfront payment and preclinical milestones including clinical development milestones and royalties on product sales to Adimab.
The tie up allows Biogen Idec with an option to commercialize antibodies generated from the collaboration.